Abbott Laboratories ABT
We take great care to ensure that the data presented and summarized in this overview for ABBOTT LABORATORIES is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABT
View all-
Vanguard Group Inc Valley Forge, PA169MShares$23.3 Billion0.34% of portfolio
-
Black Rock Inc. New York, NY131MShares$18.1 Billion0.31% of portfolio
-
State Street Corp Boston, MA77.2MShares$10.6 Billion0.35% of portfolio
-
Capital International Investors Los Angeles, CA68MShares$9.38 Billion1.51% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.1MShares$7.47 Billion1.31% of portfolio
-
Morgan Stanley New York, NY36.1MShares$4.98 Billion0.29% of portfolio
-
Geode Capital Management, LLC Boston, MA35.7MShares$4.92 Billion0.32% of portfolio
-
Jpmorgan Chase & CO New York, NY35.2MShares$4.86 Billion0.32% of portfolio
-
Wellington Management Group LLP Boston, MA26.4MShares$3.64 Billion0.56% of portfolio
-
Northern Trust Corp Chicago, IL22.1MShares$3.04 Billion0.36% of portfolio
Latest Institutional Activity in ABT
Top Purchases
Top Sells
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Insider Transactions at ABT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 25
2025
|
Andrea F Wainer EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
12,278
+12.94%
|
-
|
Feb 25
2025
|
Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
16,534
+10.41%
|
-
|
Feb 25
2025
|
Louis H. Morrone EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
10,232
+12.39%
|
-
|
Feb 25
2025
|
Mary K Moreland EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
10,712
+9.51%
|
-
|
Feb 25
2025
|
John A. Mccoy Jr. VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
4,038
+15.09%
|
-
|
Feb 25
2025
|
Robert B Ford CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
64,897
+18.55%
|
-
|
Feb 25
2025
|
Lisa D Earnhardt EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
18,788
+18.97%
|
-
|
Feb 25
2025
|
Philip P Boudreau EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
22,495
+26.79%
|
-
|
Feb 25
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
15,475
+7.17%
|
-
|
Feb 05
2025
|
Robert B Ford CHAIRMAN AND CEO |
SELL
Open market or private sale
|
Direct |
285,388
-56.46%
|
$37,385,828
$131.17 P/Share
|
Feb 05
2025
|
Robert B Ford CHAIRMAN AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
285,388
+36.09%
|
$10,844,744
$38.4 P/Share
|
Jan 30
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
58,428
-24.02%
|
$7,478,784
$128.07 P/Share
|
Jan 30
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
58,428
+19.37%
|
$2,220,264
$38.4 P/Share
|
Jan 30
2025
|
Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
23,771
-15.9%
|
$3,042,688
$128.5 P/Share
|
Jan 30
2025
|
Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
23,771
+13.72%
|
$903,298
$38.4 P/Share
|
Jan 29
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
131,360
-41.55%
|
$16,814,080
$128.35 P/Share
|
Jan 29
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
131,360
+29.35%
|
$4,991,680
$38.4 P/Share
|
Jan 28
2025
|
Louis H. Morrone EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Indirect |
2,644
-100.0%
|
$335,788
$127.39 P/Share
|
Oct 21
2024
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
157,421
-15.65%
|
$18,418,257
$117.98 P/Share
|
Oct 21
2024
|
Hubert L Allen EXECUTIVE VICE PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
157,421
+31.51%
|
$7,398,787
$47.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 196K shares |
---|---|
Exercise of conversion of derivative security | 808K shares |
Payment of exercise price or tax liability | 89.4K shares |
---|---|
Open market or private sale | 838K shares |